Skip Navigation

Annals of Oncology 2006 17(Supplement 5):v188-v194; doi:10.1093/annonc/mdj979
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lorusso, D.
Right arrow Articles by Scambia, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorusso, D.
Right arrow Articles by Scambia, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Role of gemcitabine in ovarian cancer treatment

D. Lorusso, A. Di Stefano, F. Fanfani and G. Scambia*

Department of Oncology, Catholic University of the Sacred Heart, Campobasso, Rome, Italy

* Correspondence to: Dr G. Scambia, Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Largo A. Gemelli, 8, 00168 Rome, Italy. Tel/Fax: +39 06 35508736; E-mail: giovanni.scambia{at}libero.it

Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown promising activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogues, Gemcitabine has been combined with Carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of Gemcitabine and other agents, including paclitaxel, are also feasible and have been actively studied in order to establish the role of Gemcitabine in the management of treated and untreated ovarian cancer patients.

Key words: gemcitabine, ovarian cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al.
Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.